Balance Sheet Components (Tables)

6 Months Ended

Jun. 30, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Cash and cash equivalents consisted of the following (in thousands):

	June 30, 2016		December 31, 2015
Cash	$	77,094	$	75,685
Money market funds		113,317		77,639
Total cash and cash equivalents	$	190,411	$	153,324

Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments

All investments are classified as available-for-sale. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s available-for-sale investments by major investments type are summarized in the tables below (in thousands):

	June 30, 2016
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
Corporate bonds	$	125,130	$	856	$	(5	)	$	125,981
Bond and mutual funds		25,371		56		—			25,427
Equity investments		125		112		—			237
Total investments	$	150,626	$	1,024	$	(5	)	$	151,645

	December 31, 2015
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
Corporate bonds	$	126,522	$	54	$	(473	)	$	126,103
Certificate of deposits		8,217		—		(2	)		8,215
Bond and mutual funds		25,052		—		—			25,052
Equity investments		126		71		—			197
Total investments	$	159,917	$	125	$	(475	)	$	159,567

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	June 30, 2016		December 31, 2015
Preclinical and clinical trial accruals	$	32,054	$	27,973
Payroll and related accruals		10,285		13,535
Professional services		1,041		1,662
Other		4,562		4,762
Total accrued liabilities	$	47,942	$	47,932